Physician profile
Edward E Adkins
NPI 1679561310
$9,459.66
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,847 · 2020: $1,648 · 2021: $1,661 · 2022: $2,344 · 2023: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,454.94 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $1,345.72 | 2019-2023 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $875.01 | 2019-2023 | Breztri |
| Janssen Pharmaceuticals, INC | $593.68 | 2019-2022 | |
| Lilly USA, LLC | $455.19 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Glaxosmithkline, LLC. | $448.15 | 2019-2023 | Trelegy Ellipta |
| Amgen INC. | $415.67 | 2019-2022 | |
| Pfizer INC. | $397.61 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $316.58 | 2020-2021 | |
| Amarin Pharma, INC. | $310.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.20 | 2019-2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $265.76 | 2022 | |
| Merck Sharp & Dohme LLC | $260.18 | 2019-2023 | Steglatro, Belsomra |
| Sanofi-Aventis U.S. LLC | $160.20 | 2019-2022 | |
| Allergan, INC. | $158.43 | 2020 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Adkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.